life scienc diagnost tool
preview gener posit outlook year
buy pt kick earn life
scienc tool lst sector tomorrow tuesday januari bmo
anticip big surpris result lst two five
compani coverag univers announc preliminari revenu
came in-lin rate major player sector
indic perform high-end prior guidanc rang
 govern shutdown sinc friday januari midnight
could provid near-term volatil outlook lst sector
overwhelmingli posit larg investor confer earlier month
specif near-term end market trend appear stabl longer-
term fundament industri particularli biopharma custom
emerg market demand remain healthi tax reform
expect posit impact major compani
long-term well immedi benefit compani
broke benefit term outlook
estim larg in-lin consensu buy
pt alreadi provid guidanc earlier
month estim thermo fisher scientif buy pt
modestli consensu believ larg attribut
varianc patheon contribut estim think focu
organ growth expect top pick
among larg cap compani coverag univers see btig chief
equiti deriv strategist julian emanuel januari btig top
pick note larg due rel valuat remain bullish
overal lst sector year sign improv across multipl
end market overal posit global econom outlook lst sector
strong start particularli large-cap compani ytd
vs
pleas read import disclosur analyst certif appear appendix
sinc cagrmarket state medic specialti state state pharmaceut major state pharmaceut gener state pharmaceut state servic industri state manag state hospital/nurs manag state electron equipment/instru state industri conglomer state internet software/servic state internet retail cap lstagil technolog intern fisher scientif lstbio-rad laboratori inc class cap lstfluidigm bioscienc california perform
back approxim organ growth
guidanc estim report revenu growth
y/i larg in-lin consensu includ potenti tailwind
fx current exchang rate
brkr bsi revenu order growth first nine month
mid-singl digit bode well although
qtdbrkrbtig mm ep
face challeng comparison best segment
organ revenu growth first nine month
 tax reform expect neutral increment
posit impact long-term could also see increment
benefit oversea cash repatri cash ou
think well-posit re-acceler top line growth
next month improv end market
environ combin sharper focu faster grow end
market opportun revenu today addit
believ remain disciplin oper effici
improv compani continu target bp
pre-announce preliminari revenu investor
confer earli januari januari note
model total microarray revenu growth
back growth contempl continu
strong demand consum genom
model total sequenc revenu growth
vs growth seek addit color hiseq
remov instal base replac novaseq well
commerci posit desktop sequenc miseq vs
note revenu expect slightli y/i
one-tim collabor licens revenu recogn exclud
collabor licens revenu estim revenu growth
complet ipo decemb initi report
investor confer earlier month januari
disclos preliminari revenu million
line-with consensu estim
also fulli commerci launch sr-x platform desktop
reader capabl protein dna/rna detect earlier
expect januari vs target place sr-x system
vs zero system model manag initi
expect sr-x system mainli gain traction academ
intern market find mani exist
custom augment assay develop capabl lower
revenu project million in-lin
consensu estim base roughli flattish placement
y/i sr-x placement system
expect kick guidanc organ revenu
growth done last year
regard tax reform expect tax rate reduc
level go forward provid detail
earn call current model ep
growth assum tax rate
patheon integr track earli januari januari
investor present puerto rico facil fulli back
product headwind due hurrican
capit deploy prioriti debt paydown bolt-on
model revenu growth includ
increment fx tailwind ep growth
 tax reform expect long-term benefit
three area capit alloc prioriti opportun
invest busi particularli increas flexibl
balanc sheet oversea cash strengthen
term end market rel weak first nine
month could provid easier comp
said look addit color wat outlook biopharma
spend
perform europ stronger expect first
nine month continu strength biopharma
stabil across end market asia remain solid growth
driver although disrupt expect
temporari india implement new gst good
servic tax law begin
non-biopharma end market especi industri shown
sign recoveri recent quarter ta segment
sale seen rebound benefit new product
cycl well cautious optimist non-biopharma
end market stabl even improv throughout
think reason assum end market condit
similar even slightli better compar
compani report btigagil oct fye danaherthermo tough comp good demand sciex particular strength china biopharma drove msd growth pall life scienc hsd strong bioproduct bioscienc sciex msd led pharma doubl digit growth singl use technolog msd strength bioscienc chromatographi ms research safeti market channel sustain momentum pharma test sciex pall doubl digit order growth biopharma msd strength chromatographi ms bioscienc research safeti market channel strength larg molecul biomed research declin tough expect hesit point specif project lsd similar last year sale sciex academ demand stabl across geographi lsd improv asian european market relat environment medic research applic start see sign increas activ us government fund lsd growth quarter declin msd strong perform europ china broad-bas perform across major quarter y/i declin chemic compani begin increas purchas energi explor refin busi remain challeng food test driven china enviro forens pall industri slightli environment appli solut compani averag growth strong appli market good growth research safeti market channel industri custom industri materi food environment fine chemic market grew stronger expect chemic energi growth materi mine custom also start reinvest food difficut comp environment forens sciex msd led food test environment appli solut compani averag good demand research safeti market channel industri custom environment food safeti remain strong chemic energi food grew environment forens environment appli solut msd continu benefit increas global demand particular strength across analyt instrument busi asia-pacif strength materi chemic energi food environment forens revenu y/i report revenu core revenu report revenu core revenu report revenu core revenu lsd good growth transplant biotechacadem governmentindustri applieddiagnost clinic
compani report btigagil oct fye danaherthermo msd develop market lsd north america lsd declin america us due small molecul pharma segment vs strong doubl digit growth prior year slower budgetari solid result us compani averag america us macroeconom government polici uncertainti appear affect gener busi msd solid result us lsd sale flat america us sale despit natur disast macro government polici uncertainti flat msd strength pharma robust demand industri off-set weak government academ western eu doubl digit eastern eu grew off-set solid result develop market lsd led pharma government doubl digit growth msd broad-bas growth hsd low doubl digit growth china japan flat continu strength china india ldd china high teen asia doubl digit growth china growth pharma industri doubl digit growth india japan declin difficult grew china grew hsd solid result japan china hsd hsd china mid-teen asia china grew faster overal asia doubl digit growth india continu strong china japan flat solid result japan china doubl digit ldd china high teen asia china strength across core market japan strong government academ steadi pharma growth grew faster overal asia good servic tax impact india hsd growth china asia ex china/japan lsdu americaseuropeasia pacif
btig cover compani mention report
appendix analyst certif import disclosur
